



Venetoclax (Venclyxto®)

Chronische Lymphatische Leukämie (CLL) » + Obinutuzumab (Gazyvaro®) » Erstlinie, mit Komorbidität

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
10117 Berlin

Geschäftsführende Vorsitzende: Prof. Dr. med. Claudia Baldus

Telefon: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Venetoclax + Obinutuzumab, CLL, first line, with comorbidity	... 2
---	--------------


Venetoclax (Venclyxto®)

Dokument: Fact Sheet

Spezifizierung: Chronische Lymphatische Leukämie (CLL) » + Obinutuzumab (Gazyvaro®) » Erstlinie, mit Komorbidität

Stand: Oktober 2020

1 Venetoclax + Obinutuzumab, CLL, first line, with comorbidity

Venetoclax + Obinutuzumab, CLL, first line, with comorbidity																																																					
	Facts	Appraisal	EU Approval 2020																																																		
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Parameter</th> <th style="text-align: left;">Results¹¹</th> <th style="text-align: left;">HR¹²</th> <th style="text-align: left;">p value</th> </tr> </thead> <tbody> <tr> <td>RR²</td> <td>71.3 vs 84.7</td> <td></td> <td>p < 0.001</td> </tr> <tr> <td>PFS³</td> <td>n.r.¹⁵ vs n.r.¹⁵</td> <td>0.35</td> <td>p < 0.001</td> </tr> <tr> <td>OS⁵</td> <td>n.r.¹⁵ vs n.r.¹⁵</td> <td></td> <td>n.s.¹³</td> </tr> <tr> <td>SAE⁷</td> <td>76.6 vs 78.8</td> <td></td> <td>n.s.¹³</td> </tr> </tbody> </table>	Parameter	Results ¹¹	HR ¹²	p value	RR ²	71.3 vs 84.7		p < 0.001	PFS ³	n.r. ¹⁵ vs n.r. ¹⁵	0.35	p < 0.001	OS ⁵	n.r. ¹⁵ vs n.r. ¹⁵		n.s. ¹³	SAE ⁷	76.6 vs 78.8		n.s. ¹³	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;"></th> <th style="width: 10%;">5</th> <th style="width: 10%;">4</th> <th style="width: 10%;">3b</th> <th style="width: 10%;">3a</th> <th style="width: 10%;">2c</th> <th style="width: 10%;">2b</th> <th style="width: 10%;">2a</th> <th style="width: 10%;">1b</th> <th style="width: 10%;">1a</th> </tr> </thead> <tbody> <tr> <td>Evidence (LoE)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td>Clinical benefit (ESMO MCBS)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table> <p style="font-size: small; margin-top: 5px;"> ■ curative ■ non-curative </p>				5	4	3b	3a	2c	2b	2a	1b	1a	Evidence (LoE)										Clinical benefit (ESMO MCBS)									
Parameter	Results ¹¹	HR ¹²	p value																																																		
RR ²	71.3 vs 84.7		p < 0.001																																																		
PFS ³	n.r. ¹⁵ vs n.r. ¹⁵	0.35	p < 0.001																																																		
OS ⁵	n.r. ¹⁵ vs n.r. ¹⁵		n.s. ¹³																																																		
SAE ⁷	76.6 vs 78.8		n.s. ¹³																																																		
	5	4	3b	3a	2c	2b	2a	1b	1a																																												
Evidence (LoE)																																																					
Clinical benefit (ESMO MCBS)																																																					
<table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td style="width: 15%;">Patients</td> <td>CIRS16 > 6 or creatinine clearance <70</td> </tr> <tr> <td>Trial</td> <td>CLL14, phase 3</td> </tr> <tr> <td>Randomisation</td> <td>1 : 1</td> </tr> <tr> <td>N¹</td> <td>432</td> </tr> <tr> <td>New Therapy</td> <td>Venetoclax + Obinutuzumab</td> </tr> <tr> <td>Control</td> <td>Chlorambucil + Obinutuzumab</td> </tr> <tr> <td>Publication</td> <td>DOI:10.1056/NEJMoa1815281</td> </tr> </tbody> </table>	Patients	CIRS16 > 6 or creatinine clearance <70	Trial	CLL14, phase 3	Randomisation	1 : 1	N ¹	432	New Therapy	Venetoclax + Obinutuzumab	Control	Chlorambucil + Obinutuzumab	Publication	DOI:10.1056/NEJMoa1815281																																							
Patients	CIRS16 > 6 or creatinine clearance <70																																																				
Trial	CLL14, phase 3																																																				
Randomisation	1 : 1																																																				
N ¹	432																																																				
New Therapy	Venetoclax + Obinutuzumab																																																				
Control	Chlorambucil + Obinutuzumab																																																				
Publication	DOI:10.1056/NEJMoa1815281																																																				

Legende:

¹ N - number of patients

² RR - remission rate, in %

³ PFS - progression-free survival in months

⁵ OS - overall survival in months

⁷ SAE - serious adverse events, CTCAE grade 3/4

¹¹ results for control, results for new therapy

¹² hazard ratio for new therapy

¹³ n. s. not significant

¹⁵ n. r. - median not reached

¹⁶ CIRS - Critical Illness Rating Scale